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Abstract 
Objectives:
Digital ulcers (DUs) are a major cause of disease-related morbidity and difficult to treat 
vascular complication of systemic sclerosis (SSc). Demonstrating treatment efficacy has 
traditionally focussed upon clinician assessment of DUs alone. No existing patient reported 
outcome (PRO) instrument captures the multi-faceted impact of SSc-DU.  We report the 
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Patient focus groups (FGs) were conducted across 3 scleroderma units, following a topic 
guide devised by SSc patients, experts and experienced qualitative researchers. A purposive 
sampling framework ensured the experiences of a diverse group of patients were captured. 
FGs were audio recorded, transcribed, anonymised, and analysed using inductive thematic 
analysis. We continued FGs until thematic saturation was achieved.
Results:
Twenty-nine SSc patients with a history of DU disease participated in 4 FGs across the UK 
(Bath, Manchester and London). Five major inter-related themes (and sub-themes) were 
identified which encompass the patient experience of SSc-DUs: ‘Disabling pain and 
hypersensitivity’, ‘Deep and broad-ranging emotional impact’, ‘Impairment of physical and 
social activity’, ‘Factors aggravating occurrence, duration and impact’ and ‘Mitigating, 
managing and adapting’. 
Conclusion:
The patient experience of SSc-DU is multi-faceted and comprises a complex interplay of 
experiences associated with significant pain and morbidity. Patient experiences of SSc-DU 
are not captured using existing SSc-DU outcomes. Our findings shall inform the 
development of a novel PRO instrument to assess the severity and impact of SSc-DUs for 
use in future SSc-DU clinical trials. 
Significance and Innovations:
 Existing SSc-DU outcome measures do not capture the complete patient experience 
of SSc-DU.
 The patient experience of SSc-DU is comprised of interrelated factors which 
contribute to the significant morbidity of SSc-DUs.
 Five major inter-related themes were identified: ‘Disabling pain and 
hypersensitivity’, ‘Deep and broad-ranging emotional impact’, ‘Impairment of 
physical and social activity’, ‘Factors aggravating occurrence, duration and impact’ 
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 The interplay between the themes suggest that the presence of SSc-DUs can have a 
considerable impact on patients’ physical and psychological wellbeing, impairing 
physical and social activities, and that patients expend great effort in remaining 
vigilant and managing their condition, often in innovative ways. 
 Our findings can be used to inform the development of a novel patient reported 
outcome instrument to assess the severity and impact of SSc-DU. 
Introduction
Digital ulcers (DUs) are a major cause of pain and disability in people living with systemic 
sclerosis (SSc) (1). DUs are common with around half of patients reporting a history of 
ulceration and 5-10% of people with SSc at any time have a current ulcer (2,3). DUs have a 
major impact on quality of life and hand function including occupation (4). Although we 
have a number of treatments available to both prevent and heal SSc-DUs (5–8), a third of 
patients are affected by refractory DU disease (9).
In general, demonstrating treatment efficacy in previous clinical trials has been based upon 
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agreement amongst SSc experts to classify SSc-DU is poor to moderate at best (10–12). 
Inter-rater agreement is not improved with the provision of clinical (‘real world’) contextual 
information (e.g. the severity of pain and duration of the lesion) (11). Recent negative 
clinical trials of promising therapies for SSc-DUs (13,14) have led to calls for a fresh 
approach to establishing treatment efficacy in SSc-DU (15–17).
No studies have specifically explored the patient experience of SSc-DU, although studies 
examining broader symptom burden in scleroderma have identified the major impact that 
SSc-DU can have for patients as the following quotation attests:
“..the pain that you felt in your fingers as they were dying was so excruciating that you 
almost begged to say please cut it off” (reproduced from[18])
Previous attempts to quantify the impact of SSc-DUs have used legacy patient reported 
outcome (PRO) instruments to assess broader aspects of SSc disease severity and function 
(19). There was limited or no SSc patient participation in the development of many of these 
instruments (20). The patient perspective captured by PRO instruments provides insight into 
the patient experience of disease that can not be assessed using clinician-reported 
instruments (21). Regulatory bodies, such as the FDA, seek target patient population 
involvement in PRO instrument development to ensure instruments fully capture the way 
patients ‘feel’ and ‘function’ (22).  A thorough understanding of the patient experience of 
SSc-DU is necessary to ensure a future PRO instrument captures the multi-faceted impact of 
DUs. 
Against this background, the aim of this present study was to comprehensively explore the 
experiences, attitudes and perspectives of patients with SSc-DUs. A further aim was to 
inform the development of a future SSc-DU PRO instrument.
Patients and methods
Study management
The development and conduct of the study were overseen by a dedicated steering 
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patient research partners (LM, JW), and a team of experienced qualitative methodologists 
(YA, RGH, AM). The study was approved by the East Midlands – Nottingham 1 research 
Ethics Committee (18/EM/0018) and all participants provided written, informed consent.
Study design
A multi-centre qualitative research study comprising patient focus groups (FGs) was 
undertaken at scleroderma centres across the United Kingdom (Bath, Manchester and 
London). Patient FGs create an open environment in which a broad range of experiences 
can be expressed and explored; and can often enable some (but not necessarily all) sensitive 
issues to be discussed more freely than in  a one-to-one interview setting (23). 
Participants 
Adult SSc patients (>18 years) with a history of SSc-DU, fulfilling the 2013 ACR/EULAR 
classification criteria for SSc (24) with sufficient language skills to participate in a FG 
discussion were enrolled. A purposive sampling framework ensured the enrolment of a 
diverse cohort comprising a 60:40 split between limited and diffuse cutaneous SSc (25), 
early and established disease (≤3 and >3 years since first non-Raynaud’s phenomenon 
symptom, respectively), a spectrum of historical DU disease, sex (aiming for 5:1 female 
predominance) and ethnicity (e.g. with Caucasian and Black British). The FGs sought to 
include 6-10 participants to enable open discussion whilst ensuring that each participant 
had the opportunity to express their personal experiences, interact and offer alternative 
opinions should they wish. A minimum of two to three FGs was expected to be necessary in 
order to achieve ‘thematic saturation’ but the intention was to continue enrolment until 
there was consensus that no meaningful new experiences were being shared by participants 
or warranted further exploration by the investigators (26).
Data collection
Each FG lasted approximately one hour in duration and were all facilitated by MH, with the 
first focus group also facilitated by JP and AM to ensure that there were no issues including 
a need to revise the topic guide (which was not the case). FGs were facilitated by 
rheumatologists (MH and JP) with experience in the clinical heterogeneity and management 
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ambient environment without external distraction. The FG lead facilitator (MH) is 
rheumatologist with an interest in SSc and was not directly involved in the clinical care of 
the participants. JP is a rheumatologist with an interest in SSc and AM is an experienced 
qualitative researcher/methodologist. A relaxed environment in which each participant’s 
views were sought, valued and respected enabled individuals to share experiences of SSc-
DU and allow others to express similar or opposing views. The FGs were audio-recorded and 
subsequently transcribed verbatim, with all the context anonymised. A topic guide was 
developed with input from the study steering committee (see supplementary material). 
Each FG started with broad open questions asking participants to describe their experience 
of their disease and DU history. FGs adopt an adaptive study design enabling incompletely 
explored or newly emerging themes to be investigated to ensure thematic saturation was 
achieved. 
Data analysis
Qualitative analysis was conducted by JJ and AM, both experienced qualitative 
methodologists, with further input from the wider team (MH, JP, RGH and patient partners). 
NVivo 11 software was used to manage and interrogate the data. Transcribed data were 
analysed using thematic analysis (26). First, JJ read and re-read transcripts to ensure 
familiarity with the content. Information relevant to patients’ experience and understanding 
of DUs was then coded using descriptive labels. Codes that occurred repeatedly, or that 
shared conceptual similarities were then grouped together to form initial categories. The 
initial set of codes and categories were then discussed with the wider team (AM, MH, JP, 
RGH) to ensure it captured all elements from the focus group. The coding framework was 
then applied to subsequent transcripts and any newly identified codes added as 
appropriate. The FG facilitators decided when data saturation had been reached (27). Codes 
were collated and grouped into themes and sub-themes. Coded data within each theme was 
checked to ensure internal coherence (fit within the pattern of the theme) and external 
representativeness (fit within the whole data set). JJ and AM regularly discussed the 
conceptual development of the themes and subthemes and an analysis de-briefing meeting 
was convened involving (JJ, AM, RGH, JP) to discuss the final theme groupings and the 
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Our approach was both deductive, in the sense that the research team examined pre-
conceived considerations on the impact of DUs (derived from an earlier comprehensive 
literature review (19)) and how participants understood and managed them, for the 
purposes of developing a PRO instrument, and inductive in the sense there was no pre-
existing coding frame and the developing codes were derived from and grounded in the 
data themselves (28).
Results 
Twenty-nine patients with SSc participated in 4 FGs conducted in Bath (n=8), Manchester 
(n=7) and two FGs in London (n=6 & 8). Our a priori purposive sampling framework ensured 
that we studied a broad study population of patients with SSc and DU disease (Table 1). 
Thematic saturation was felt to have been achieved after 4 FGs.
Five major themes emerged, that together constitute the patient experience of SSc-DUs: (i) 
disabling pain and hypersensitivity, (ii) deep and broad-ranging emotional impact, (iii) 
impairment of physical and social activity, (iv) factors aggravating occurrence, duration and 
impact,  and (v) mitigating, managing and adapting to ulcers. The 5 constituent themes (and 
subthemes) can be arranged within a conceptual map of the patient experience of SSc-DUs 
(Figure 1).
Theme 1: Disabling pain and hypersensitivity (Table 2)
Our study found that pain is a cardinal symptom of SSc-DUs and is often very severe (Q1-4). 
Participants used a wide range of words and phrases to describe the severity of pain such 
as: ‘excruciating’, ‘pain that could reduce you to tears’, ‘agonising’ and ‘unbearable’. 
Participants often described the pain as pulsatile or throbbing in nature (Q5-6), including a 
pressure like effect (Q7). Not all participants used the word ‘pain’ to describe the physical 
discomfort of SSc-DUs; other expressions included ‘soreness’, ‘tenderness’ or ‘discomfort’. 
The level of reported pain was often considered as being disproportionate to the size of the 
DU (Q8). DU pain can radiate to the other digits and proximally (Q9-10). Co-existent 
infection of the ulcer increases DU pain (Q11) and some participants reported that changes 
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where previous ulcers had occurred, whereas, others said the area was tender, sore or 
sensitive, and could be aggravated by touch or exposure to cold (Q13-15). Other sensations 
in areas of previous ulcers included tingling nerve-like sensations and partial or complete 
numbness (Q16-17). One participant said, “it’s never the same again” (P6 M1) when talking 
about the area where previous ulceration had occurred. Due to the severity of DU pain, 
some participants suggested that invasive procedures (including digital amputation) may be 
both necessary and appropriate to relieve symptoms (Q1, Q4, Q5, Q7, Q18, Q24). Across all 
the FGs, participants talked about the need to validate the pain they experienced with 
friends, family and colleagues (Q19-22). Participants described the severity of their ulcers in 
different ways. These included the need for hospitalisation, the time to heal, changes in 
their life (e.g. giving up work or hobbies) due to ulcers, and previous/risk of amputation 
(Q23-24). There was a wide variety in the reported location (fingertips, over the small joints, 
under the nails and on the sides of the fingers) of DUs amongst participants. Some 
experienced ulcers in different locations on the hands, whereas, others tended to only get 
ulcers in one area. 
Theme 2: Deep and broad-ranging emotional impact (Table 3)
Related to the severity of pain, most participants shared a constant fear of the development 
of new DUs (Q25) and many considered it inevitable that further lesions would develop 
(Q26-27). Participants experienced anxiety/uncertainty around how severe each ulcer 
would be, whether they were treating the ulcer correctly, and how long it would take the 
ulcer to heal (Q28). Although most participants did not explicitly say that ulcers caused 
them depression (Q29), they mentioned many associated emotions (in addition to anxiety 
and embarrassment) including uncertainty/fear for the future and anger (Q29-32). 
Participants described the need for a constant level of vigilance to prevent the development 
of new DUs and infection of intercurrent ulcers (Q33-34). Participants described many 
different emotions associated with the ulcers from panic, anxiety, fear and irritability to 
anger (Q35). Participants did not forget about the past impact of the ulcers and some 
described frightening times (with current ulcers) when they were perhaps unsure whether 
they would need to have part of their finger amputated (Q24). Patients also experienced 
embarrassment and distress due to the physical appearance of SSc-DUs and took a range of 
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Theme 3: Impairment of physical and social activity (Table 4)
The physical and psychological impact of SSc-DUs was closely related to impact on physical 
and social functioning. Patients interactions with the world and other people were 
characterised by an avoidance of pain, and a constant vigilance during physical and social 
interaction. Participants reported about how DUs impacted on their ability to use their 
hands during activities of daily living (Q41-46), including self-care/grooming (Q38, Q47-48), 
hobbies (Q49) and domestic activities (e.g. cooking and household chores) (Q13, Q50-51). 
Taken for granted activities of daily living became foregrounded, such as their ability to 
reach their hands into pockets, a bag or a purse (Q45, Q52-53), difficulty driving (Q30, Q54), 
sleeping (Q55) and challenges when shopping (Q12, Q56-57). Impact of DUs on work varied 
between the participants. For some participants, ulcers had not severely impacted on their 
work, whereas, others had to change roles in the organisation or even change jobs 
completely (58-59). Some participants described financial concerns from the impact of DUs 
on their work (Q60). DUs impact on social participation and participants reported taking 
measures to conceal ulcers with bandages or gloves to both avoid others seeing them and 
to reduce the risk of infection (Q61-62). A number of participants described difficulties 
undertaking caring roles within the family; for example, avoiding taking their children 
outside to play due to the cold weather (Q63) as the cold both exacerbated the pain, but 
could also aggravate the healing of ulcers, or provoke their onset. 
Theme 4: Factors aggravating occurrence, duration and impact (Table 5)
There were a number of factors that aggravated the occurrence and duration and impact of 
ulcers. There was variation in the number of ulcers experienced by participants; ranging 
from experiences of solitary DU to recurrent episodes of refractory digital ulceration (Q24, 
Q26, Q64-66). There was variation amongst participants on the time to DU healing (weeks, 
months or even years). The length of time to heal was often related to the season and 
treatment. Most participants reported that over the winter it took longer for ulcers to heal 
(Q67), or they did not heal at all until the summertime (Q68). Most participants seemed to 
be able to identify where previous ulcers had occurred either based on how they looked or 
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Theme 5: Mitigating, managing and adapting to ulcers (Table 5)
Participants used a variety of ways to describe whether a treatment had been effective or 
not. This included: whether and how quickly the ulcer had healed; if there had been a 
reduced rate of recurrence of the ulcer; how the appearance of the ulcer had changed; 
whether the level of pain was reduced; positive impact on other activities such as sleeping 
and whether the participant thought circulation had improved; if the wound dressing had 
been effective in protecting the ulcer, and whether the risk of amputation was reduced 
(Q69-73). As well as the effectiveness of treatment, participants also alluded to the burden 
of treatment. This could mean the need for hospitalisation or the burden of medication, the 
duration (time) of receiving treatments or the severity of associated side effects, and the 
time and ease of putting on bandages (Q74-75). Participants discussed a range of coping 
strategies to manage DUs including different ways in which they had adapted or used 
support in order to cope with their ulcers. This included using a device or aid to help 
manage ulcers (Q76-77), strategies to avoid causing pain or preventing a new ulcer 
developing (Q78-79) and getting help or support (paid or unpaid) from others (Q80). Several 
participants talked about how their children have adapted to the condition and help them 
cope with limited function (Q80). However, some noted that it was not possible to avoid all 
activities which may aggravate the ulcer especially if they have young children (Q81). 
Participants described a variety of techniques they used to manage their ulcers, from the 
earliest stages of development to when the ulcer is visible and active. These included using 
‘home remedies’ and alternative treatments (Q82), wound care (Q83), the vigilance 
associated with self-management (Q84-Q85) and avoiding behaviours (e.g. cold exposure) 
that they consider can cause ulcers (Q86).
Discussion
The present study is the first to specifically explore the multi-faceted patient experience of 
SSc-DU. We have identified 5 major inter-related themes (and subthemes) which constitute 
the patient experience SSc-DUs that we have organised within a conceptual map of SSc-DU. 
The major themes comprised ‘Disabling pain and hypersensitivity’, ‘Deep and broad-ranging 
emotional impact’, ‘Impairment of physical and social activity’, ‘Factors aggravating 
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The multi-centre study design and purposive sampling framework ensured we captured the 
experiences from a broad cohort of SSc patients and the spectrum of SSc-DU disease (from 
solitary DUs to recurrent refractory disease). Thematic analysis of the FG transcripts was 
conducted by experienced qualitative researchers without direct experience in the 
management of SSc-DUs, avoiding the potential bias that pre-conceptions held by 
scleroderma clinicians might have introduced. The study benefited from a broad 
international steering committee of SSc experts, qualitative researchers and patient 
research partners.
Painful physical symptoms and signs were the most important experiences of SSc-DU. Pain is 
the cardinal symptom of SSc-DUs and is often very severe. Patients often consider the 
severity of pain disproportionate to the physical size of DUs. Infection and changes in 
temperature can worsen DU pain. The physical symptoms of DUs results in considerable 
psychological distress, and impaired hand function impacts on all the activities of daily living 
including occupation and social interactions. Many patients describe a constant state of 
vigilance both during and between episodes of ulceration. There are a number of 
aggravating factors including the number and severity of DUs. Of interest, participants 
reported that the ulcers took longer to heal during the winter, and residual symptoms at 
sites of previous DUs. In particular, dysesthesias and paraesthesias could suggest persistent 
nerve damage. Patients with SSc make considerable efforts to both prevent and manage 
DUs (e.g. avoiding trauma and preventing infection) and describe a wide range of coping 
strategies and adaptations. This mirrors the patient experience of SSc-Raynaud’s 
phenomenon, in which patients report the need for constant vigilance & self-management 
(29). Overall, our themes show similarities to those reported by Nakayama et al who 
conducted a systematic review and thematic analysis of 26 studies with 463 patients’ to 
explore patients perspectives and experiences living with SSc (29). The 6 key themes were: 
‘distressing appearance transformation’, ‘palpable physical limitations’, ‘social impairment’, 
‘navigating uncertainty’, ‘alone and understood’, and ‘gradual acceptance and relative 
optimism’ (29). Furthermore, DUs (along with Raynaud’s phenomenon and calcinosis) were 
described as ‘being intensely painful by some patients’, was ‘emotionally distressing’, and 
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As previously described, previous clinical trials of SSc-DUs, primary assessment of treatment 
efficacy has focussed on clinician assessment of DU presence alone (occurrence and 
persistence) and have largely overlooked the patient experience of SSc-DUs. Legacy PRO 
instruments assessing function and interference capture patient experiences relevant to 
SSc-DUs, but are limited by the inclusion of redundant items which are less relevant to SSc-
DUs (e.g. the inclusion of non-hand domains of the HAQ-DI). The recent development of a 
SSc-specific PRO instrument: the Hand Disability in SSc DUs (HDISS-DU) was developed 
through modification of the Cochin Hand Function Scale including qualitative patient 
interviews to assess the impact of DUs on hand function in patients with SSc (30). However, 
to date, other important experiences of SSc-DUs (e.g. psychological impacts and social 
participation) have been comparatively overlooked. The development of a novel PRO 
instrument that captures the broader patient experience of SSc-DU (e.g. relationships and 
body image dissatisfaction) would be valuable for assessing interventions in clinical trials, 
but also in clinical practice, where there is a dearth of practice-based evidence examining 
the comparative efficacy of different pharmacological, surgical and wound care protocols. 
Furthermore, even after ulcer healing, patients can still suffer from significant residual pain 
and anxiety of future DUs. Therefore, effective ulcer treatments (and PRO instruments) 
should also modify future patient (negative) experiences of DU disease even after ulcer 
healing.
Our analysis has not addressed potential differences in experiences relating to DUs 
occurring at different locations on the hands (e.g. fingertip vs extensor). The 
aetiopathogenesis (and patient experience) of different types of DU may differ, although it 
is generally accepted that all types of DU have an ischaemic contribution (31,32). Therefore, 
future efforts to develop a dedicated PRO instrument for assessing SSc-DU should explore 
different experiences (including treatment effects) at different ulcer locations. We also 
highlight that we only recruited a relatively small number of patients with ‘early’ disease. 
This is likely due to the need in our study to include a large majority of patients with a 
significant burden (history) of digital vascular disease, which usually takes time (years) to 
accrue. There were differences observed in the clinical and demographic characteristics (e.g. 
age and gender) of participants who participated in the four FGs. For example, the majority 
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approximately equal numbers of patients had diffuse disease in the two London FGs. We did 
not entirely achieve our intended purposive sampling framework but we were satisfied that 
we had captured the experiences of a broad spectrum of patients and did not feel this was a 
barrier to achieving the study’s aims. Due to the rarity and heterogeneity of the disease, it is 
not always possible to identify and enrol patients with specific phenotypes to studies of this 
nature. We also excluded participants that could not speak English. Although our FGs were 
conducted only in the UK, previous studies (including multi-national recruiting clinical trials) 
have demonstrated no important differences in DU disease between countries. In our study 
we captured limited information on the impact of SSc-DU on intimate relationships (18). It is 
likely that if the data had been collected during one-to-one interviews, then comments on 
the impact of DUs on intimate relationships would have arisen and should be considered in 
the design of future research. We shall explore such themes in a 1:1 setting during future 
cognitive de-briefing of a provisional item-bank for the proposed DU PRO instrument.
It should be highlighted that treating clinicians (MH and JP) facilitated the FGs which could 
have impacted on the reflexivity of the research and introduced potential bias, for example, 
by shaping the discussion and/or limiting patients’ willingness to discuss certain aspects of 
their experience. However, mitigating factors include the study topic guide which was 
developed with support from patient insight partners and used to inform the structure of 
the FGs. Patients were only known to one individual clinician at one geographical location. 
Furthermore, while background clinical knowledge of SSc was essential to successfully 
facilitate the FGs, the analysis of data was led by two independent researchers (JJ and AM), 
to mitigate this potential source of bias.
In conclusion, ours is the first study to examine the multi-faceted patient experience of SSc-
DUs. Traditional clinical trial end-points are not currently designed to capture the patient 
experience of SSc-DUs, which should be a key priority for demonstrating meaningful 
treatment benefit.  The resultant themes and subthemes from our study provide a unique 
insight into the patient experience of SSc-DUs. This work could form the basis of a novel 
PRO instrument to assess the impact and severity of SSc-DUs to support much needed new 
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Table 1: Demographics and clinical phenotype of enrolled participants according to 
purposive sampling framework. 
DcSSc, Diffuse cutaneous systemic sclerosis; DU, digital ulcer; LcSSc, limited cutaneous 
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Demographics/clinical 
phenotype
Bath Manchester London (1) London (2) Overall
Number of participants, n 8 7 6 8 29










Sex (F:M), n 7:1 7:0 3:3 3:5 20:9
LcSSc 8 6 2 4 20Disease 
subtype, n DcSSc 0 1 4 4 9






















Early 0 1 1 0 2Early vs 
established 
disease^, n Established 8 6 5 8 27
1 previous DU 1 1 0 1 3
2-4 previous 
DU
3 3 2 1 9
History of 
DU, n 
≥5 previous DU 4 3 4 6 17
White/ 
Caucasian
7 6 5 5 23
Black British 0 1 1 2 4
Ethnicity, n
Asian 1 0 0 1 2
None 1 2 1 2 6Vasodilator 
medication 
usedǂ, n Calcium 
channel blocker























3 2 2 2 9
* Since first non-Raynaud’s symptom. ^ Early and established disease (≤3 and >3 years since 
first non-Raynaud’s phenomenon symptom, respectively). ǂ Indication not specified and 
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Table 2: Quotes supporting the “Disabling pain and hypersensitivity” theme of the patient 
experience of SSc-DU.
Q refers to the numbered quote cited in the text. B1 denotes Bath group; M1 denotes 
Manchester group; L1, L2 denotes London groups; S # denotes subject (participant) number 
within each focus group.
Subtheme Q Subject Quotation
Disabling pain and hypersensitivity
1 P1 M1: The pain is just unbearable, in fact you just want to chop your finger off don’t you? You think well I’d 
rather have my finger chopped off than have that pain. I have, I’ve got to the point where I think just 
take it off. I can’t stand it
Pain
2 P8 B1: When the pain is really bad you, you just rock back and forward like this
3 P1 M1: the pain, I just wanted to sit on the floor and cry … the pain is the worst thing I’ve had
4 P6 M1: I just want it off. It needs to go, it gets that bad. You think, sorry, you feel like you want to bang your 
head to refer the pain somewhere else, just to relieve it
5 P7 L2: You just want to take your finger off, that’s how bad it is. The pulsating painPulsatile/ 
throbbing 6 P7 L2: Like someone’s getting a nail and hammering a nail right through the tip …. And keep going and going, 
because it just keeps going through the finger





8 P5 M1: It’s quite incongruous the amount of pain from the minimal amount of disruption to your thumb
9 P2 B1: The pain started actually in the finger bed, and I could feel it tracking along the finger and it dipped down 
into the first joint, so I could actually feel the pain in between the two joints
Radiation 
10 P7 B1: So the ulcer is in the middle but I’ll still get pain in the index and ring finger which is equivalent to the 
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Infection 11 P5 L1: I try not to get mine infected because then the pain level goes up
Tempera-
ture
12 P2 L1: It’s almost impossible to go in, in the summer when they’ve got the air conditioning on, it’s not just the 
frozen aisles, it’s the whole supermarket…. if you’ve got an ulcer, the change in temperature will make 
the ulcer sensitive like a nerve, you can really feel it
13 P1 B1: I don’t go near the freezer for that reason, but even a cold bottle of milk in the winter, if you take it out 
of the fridge that’s enough to set things off. …where I’ve had the ulcers, particularly that one it, it 
becomes painful
14 P3 M2: It’s really tender if I just catch me finger now, but I, luckily I haven’t had any more since then, it just left a 
lot of tenderness on, on the tips of me fingers… it’s just the pain where I had the ulcer that’s where it’s 
straight away, the cold, as soon as I go out
15 P1 L1: It’s the very end of the fingers, it’s extremely, erm, sensitive and it doesn’t matter if it looks like an ulcer 
sort of wound, or it might be completely healed up it can still be extremely sensitive to touch
Pain/ 
sensitivity 
at sites of 
past ulcers
16 P3 B1: Just a slight tingly nerve sensation now, no pain
Numbness 
at sites of 
past ulcers





18 P7 M1: It’s just so painful that the idea of cutting my finger open to take it out seems better than having that 
pain all the time
19 P4 B1: Going back to what you said just now about people seeing it, sometimes you almost want to show, 
because you can’t explain the pain you get with them, you almost want to show people this is what it’s 
causing. My family’s seen them obviously but I couldn’t get it across
20 P1 B1: Seems a bit feeble ringing and saying I can’t come to work ‘cause my finger’s hurting doesn’t it?”




22 P1 M1: But you could cry with them, it is, you could sit down and cry and you can’t explain to anyone in your 
family how bad the pain is
Description 
of severity
23 L1 P5: It was very difficult to be an electrician. Erm, I think, er, the difficulty is the severity of the winter, as you 
get the ulcer appear during the winter and then it’s the amount of time after the winter they take to heal 
up
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Table 3: Quotes supporting the “Deep and broad-ranging emotional impact” theme of the patient 
experience of SSc-DU.
Q refers to the numbered quote cited in the text. B1 denotes Bath group; M1 denotes 
Manchester group; L1, L2 denotes London groups; S # denotes subject (participant) number 
within each focus group.
Subtheme Q Subject Quotation
Deep and broad-ranging emotional impact
Fear 25 P1 M1: I don’t particularly want to go out when I’ve got one because I’m so frightened of getting in the car and 
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26 P5 L1: I don’t know if it’s a good or bad thing but I’ve got used to having them so it becomes a way of life …. 
when I used to maybe have one a year, I used to think it was quite a big deal but then since getting five 




of DUs 27 P4 L2: Because you can probably guarantee you are going to get another one sometime… I don’t see how you 
can prevent it, if it’s going to happen, it’s going to happen. I don’t see how it could be…
Anxiety/ 
uncertainty
28 P7 M1: I’m still learning about the whole thing so it changes every day, I call it the Hunger Games, when 
something starts to get better something else happens and you don’t know what is happening so the 
answer is I don’t know what brings them, I don’t know what I do wrong or not wrong…. it’s one of the 
worst things about the disease because it makes you scared and it makes you nervous, irritable
29 P2 L2: It affected me quite a bit, yes… it really depressed me at that time
30 P1 M2: It’s like a black cloud isn’t it? …. It doesn’t tend to go away does it? … Some days you just think well I’m 
not thinking about it and then other days it …. It gets you down a bit don’t it?”
31 P7 M1: Just angry all the time because you have to be conscious and you can’t relax
Depression
/ anger / 
uncertainty 
about the 
future 32 P6 L2: It really, it ruins the day, it changes your life
Constant 
vigilance
33 P3 M1: you do feel very cautious, if you, if you do have a bang then you’re more, erm, aware that you’re not to 
do things for the next few days in case it, it goes really bad
34 P1 M1: Well I’ve got to be particularly careful now if me nails grow, especially at the side I’ve got to try and cut 
them… and then of course you’re worried when you cut them that you’re not going to do any damage as 
well, so it’s a bit difficult really
Anger 35 P7 M2: Just angry all the time because you have to be conscious and you can’t relax… And it affects you, yes, it 
affects you and it affects the kids, it affects everything around you. You have to tell yourself all the time, 
you’ve got this, you have to, you have to remember your hand all the time
36 P8 B1: I used to hide mine under the table cloth at a function…. Embarrassment, probably
37 P4 B1: You don’t want other people be distressed at seeing them, also it’s protection against infection
38 P2 B1: So I kept them covered up and I’ve got photographs in my bag that I took for my own record really, you 
know, and my son said last time ‘don’t you let me see those, I don’t want to see them…’ but even the 
doctors never looked at my fingers when I had the ulcers
39 P7 L2: Sometimes it looks awful, all the skin peeled back and it’s all exposed, yeah, you just hide it… I just don’t 






40 P4 B1: If I was going out to a social function or meeting friends or something I would put plasters on, because 
it’s better for someone to see plasters than, you know, and your friends get used to the fact of, how’s 
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Table 4: Quotes supporting the “Impairment of physical and social activity theme of the patient 
experience of SSc-DU.
Q refers to the numbered quote cited in the text. B1 denotes Bath group; M1 denotes 
Manchester group; L1, L2 denotes London groups; S # denotes subject (participant) number 
within each focus group.
Subtheme Q Subject Quotation
Functional Impacts of SSc-DUs
41 P1 L1: Just trying to handle things with your fingers, you just have to careful you don’t drop a tea cup, your 
dexterity goes
42 P5 L1: Where the ulcers were, sort of like stop the movement in your hands so I wasn’t able to do these things 
that I needed to do
43 P4 L4: To actually bend the fingers where your ulcers are actually on top of the knuckles is practically 
impossible
44 P4 B1: That’s the thing, that’s what I say, I can get things done, but I cannot do it at the speed that I used to 
before






46 P6 M1: It’s like opening a bag of crisps if you’re out for a drink, I can’t open the crisps
Self-care/ 
grooming
47 P1 M1: I’m frightened of catching it. You don’t want to get dressed in case you’ve got to zip something up and 
you catch it
48 P5 L1: Even just going and brushing our teeth it’s painful when our hands are sore and ulcerated
Hobbies 49 P2 B1: I’ve had to stop doing things like knitting….Because they flare up straight away and open and it doesn’t 
matter whether I use natural fibres it’s just the irritation of my skin so I had to give up knitting…. I have 
to be very careful gardening
Domestic 
activities
50 P6 L1: Two years ago I can do nothing really, so I needed help my daughter, husband, everyone doing 
something at home. I could do nothing, cooking
51 P8 L2: It’s impossible to make the bed, I can’t put my hand, I can’t put the sheet under
52 P4 M1: When it starts to crust over that, that’s when I can’t go in me bag, you know, and you just tip everything 





53 P1 L1: Putting your hand in your pocket can be horrendous if you hit a key or something like that
Difficulty 
driving 
54 P4 B1: Things to try and protect it, ‘cause you’re guaranteed knocks on every single day, you carefully put the 
ignition key in the car, you still knock this one on the steering wheel and things like that
Sleep 
disturbance
55 P1 M1: It’s like somebody’s sticking a needle in your finger when you’re trying to go to sleep, you could hold 
your hand in the air
Shopping 56 P4 L1: Going to supermarkets I can’t go up and down the fridge aisle. I have to stand there and wait and think 
about do I need anything down there, but even just going into a supermarket, it’s just too cold… Because 
you have to balance your bags so that you can carry them, if they’re rushing you, you’re just dropping 
everything in and it’s all falling out and it just becomes a disaster
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but I’m sort of thinking I’m holding the queue up and I suddenly hear this voice behind me saying, ‘you 
don’t have to rush you know’ [laughing], people are nice I find
58 P3 L1: Well I was a programmer so it wasn’t a difficult job to carry on doingChange in 
working/ 
occupation
59 P7 B1: Obviously it’s affected a lot of the work that I do as well. There’s only 50% of the work that I used to do 




60 P7 B1: Most people have said you need to change your job, but once you’re set up and you’re established and 
you’ve got a wife, kids, a mortgage and bills to pay, it’s impossible to go back and start as tea boy again 
somewhere else, so you carry on but you’ve got to try and adjust what you do to maintain your income, 
that’s the biggest difficulty I’ve had so far
Concealing 
ulcers
61 P4 B1: You don’t want other people be distressed at seeing them, also it’s protection against infection and also, 
you know, if you’re going out to any social function I will bandage….  I did go to my daughter’s wedding 
which was in all of this, and so I did wear my black gloves all through the wedding
62 P5 L1: I don’t know if it’s them or myself thinking, oh are they thinking I’m contagious or that kind of thing, 
because they look horrible when they’re at their worst, but now I’ll try to keep them, I’ll keep them 
covered if they’re… I wouldn’t go out anywhere without them being covered but still when you’re 





63 P7 B1: It changes the way you have to think of it, everything that you do. I mean the wife says to me, do you 
want to take the kids down the fair, and the first thing I have to do is check the temperature outside, you 
know. If it’s 20° or less, I’ll bail out, I wouldn’t bother going, but it’s not nice because you miss out on a 
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Table 5: Quotes supporting the “Factors aggravating occurrence, duration and impact” and 
“Mitigating,  managing and adapting” themes of the patient experience of SSc-DU. Q refers to the 
numbered quote cited in the text. B1 denotes Bath group; M1 denotes Manchester group; 
L1, L2 denotes London groups; S # denotes subject (participant) number within each focus 
group.
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Factors aggravating occurrence, duration and impact
Number of 
ulcers
64 P3 M1: I have only had one ulcer, erm, which was really quite bad. Erm, and it, I was put on a drip in hospital with, 
is it Epoprostenol, twice to see if that would help, erm, but it didn’t and they ended up going to theatre to 
have it cleaned out, erm, and it’s just, and that’s the only ulcer I’ve ever had
65   P4 B1: I’ve had, erm, I was diagnosed with limited scleroderma approximately 28 years ago, erm, which started 
with an ulcer in one finger and just gradually got worse over the years with anything up to four or five 
ulcers every winter, which sometimes cleared up in the summer, yeah, so on-going
66   P2 L1: When I was first diagnosed ulcers weren’t really a problem. I might have one a year but as the scleroderma 
has progressed I have had up to 10 ulcers at a time on my hands, erm, in different degrees of severity
67 P4 M1: They get easier in the summer, they heal betterUlcers heal 
slower in 
the winter
68 P4 L1: They hey just would erupt through the whole winter and then I’ve got to wait till the middle to the end of 
the summer, then I get a short respite
Mitigating, managing and adapting to SSc-DUs
69 P1 B1: Being able to sleep during the night with the bearable pain would be an absolutely added bonus
70 P7 B1: Well within five days that finger healed up more than it did in three months so the minute I came in on the 
Iloprost, …. certainly the five days I spent here last week, I wouldn’t be as healed up as I am now, and able 
to work again
71 P7 L2: If the pain stops





73 P5 L1: I just find it keeps them at bay. I worry that if I was to lengthen it again it would just be worse, erm, so 
yeah, it sort of helped the aggression that you say, the inflammation and things
Burden of 
treatments
74 P4 B1: I think I would definitely say it’s helped a lot and it’s kept me out of hospital. I’ve managed, the ulcers are 
still taking several weeks, if not months to heal but they do heal without the need to intervene with 
Iloprost on top and a stay in hospital, presumably that’s an extra cost to the NHS and it’s better for me 
‘cause I’m not in hospital
75 P3 L1: It takes forever to get them on and get them off and then you realise that the reason they’re hurting more 





76 P8 B1: I keep a pair of gloves up on top of the fridge freezer to do just that, you know, to take anything out from 
the freezer
77 P4 L1: I’ve got things that help me grip jars
78 P1 L2: I also wear gloves, ‘cause every time you hit it on something it flares more, that is a big problem I’ve got no 
matter, if you touch it, or anything you touch, once you hit it, it flares up again
79 P8 L2: The other thing that I’ve done for the last 18 months, I never, ever, wet them, as least as possible to get 
them wet, so in the shower I’ve got rubber gloves
Support 
from others
80 P4 L1: They’ve adapted, my children have, I mean they’re grown up now, but they just know I’ll just call, they walk 
in, open a bottle, if I’m cooking and if I look, they know which one, which saucepan to get out, they just 
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81 P7 M1: I have three children, erm, and I live alone and it’s not easy because you have to do everything, so you have 
to cook, you have to touch water and that is something that terrifies you,… It is very difficult but the way to 
cope about it, I think it is just to explain to them …. and they will know that they have to step up to do 
something of the things so they, they understand that part, but the other part that you have to live, you 
have to do it, you have to bath them, you have to do everything else, and you know that you’ll be in pain 
for that time, all the time. You know it’s going to happen whether you like it or not
82 P1 L4: It’s really good, the pumice stone really helps peel it down
83 P7 L2: I think the hardest thing is trying to treat it, and put bandages on it because it’s such awkward positions, 
you can’t keep the bandage on there and do other things
84 P2 L1: It’s just a lot of care that I have to take, and just move very, very slowly, be very aware of your space 





85 P3 M1: You do feel very cautious, if you, if you do have a bang then you’re more, erm, aware that you’re not to do 
things for the next few days in case it, it goes really bad.” 
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Figure 1. A conceptual map comprising the five major inter-related themes that constitute 
the patient experience of SSc-DUs. The manifestation of pain that is often unbearable 
affects both the day-to-day functioning of the individual and their psychological well-being. 
For example, an inability to physically manipulate the world through their hands, can lead to 
avoidance of activities or social interaction and subsequently cause low mood. This can be 
supported through the use of aids and devices, such as gloves, or help from other people.
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